• VSE stock is holding steady today. What’s ahead for VSE stock?Mullin Bets on Small-Cap/Mid-Cap StocksMullin reported the purchase of 10 stocks in a new disclosure, according to the Benzinga Government Trades page. The stock purchases were all made on Jan. 5, 2026, with Mullin reporting two purchases of $15,000 to $50,000 of each of the 10 stocks. Here are the stocks and their market capitalizations:  A quick glance at the stocks bought by Mullin shows that the majority trade with market capitalizations u ...

Top information technology (IT) services companies are racing to deploy artificial intelligence agents from specialist firms across their domains, at a time when the debut of advanced AI tools threatens to eat their lunch. Four of the country’s largest IT outsourcers—Cognizant Technology Solutions Corp, Infosys Ltd, HCL Technologies Ltd, and Wipro Ltd—are partnering with smaller firms and adopting their AI agents for software development, data analysis and marketing, highlighting the business transformation ...

For the quarter ended December 2025, Boyd Gaming (BYD) reported revenue of $1.06 billion, up 2% over the same period last year. EPS came in at $2.21, compared to $1.96 in the year-ago quarter.The reported revenue represents a surprise of +5.73% over the Zacks Consensus Estimate of $1 billion. With the consensus EPS estimate being $1.88, the EPS surprise was +17.3%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectati ...

Lionsgate Studios Corp. (LION) reported $724.3 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 1.5%. EPS of $0.01 for the same period compares to $0.22 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $706.03 million, representing a surprise of +2.59%. The company delivered an EPS surprise of -50%, with the consensus EPS estimate being $0.02.While investors closely watch year-over-year changes in headline numbers -- revenue and ear ...

For the quarter ended December 2025, Cousins Properties (CUZ) reported revenue of $253.34 million, up 15% over the same period last year. EPS came in at $0.71, compared to $0.09 in the year-ago quarter.The reported revenue represents a surprise of +0.49% over the Zacks Consensus Estimate of $252.1 million. With the consensus EPS estimate being $0.71, the company has not delivered EPS surprise.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expecta ...

Synaptics (SYNA) reported $302.5 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 13.2%. EPS of $1.21 for the same period compares to $0.92 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $299.83 million, representing a surprise of +0.89%. The company delivered an EPS surprise of +5.22%, with the consensus EPS estimate being $1.15.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall ...

For the quarter ended December 2025, Ventas (VTR) reported revenue of $1.57 billion, up 21.7% over the same period last year. EPS came in at $0.89, compared to $0.13 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.5 billion, representing a surprise of +4.68%. The company delivered an EPS surprise of +0.38%, with the consensus EPS estimate being $0.89.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expect ...

For the quarter ended December 2025, Coursera (COUR) reported revenue of $196.9 million, up 9.9% over the same period last year. EPS came in at $0.06, compared to $0.08 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $191.78 million, representing a surprise of +2.67%. The company delivered an EPS surprise of -5.21%, with the consensus EPS estimate being $0.06.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Reddit Inc. (RDDT) reported $725.61 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 69.7%. EPS of $1.24 for the same period compares to $0.36 a year ago.The reported revenue represents a surprise of +8.71% over the Zacks Consensus Estimate of $667.48 million. With the consensus EPS estimate being $0.96, the EPS surprise was +29.3%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall ...

Core Viewpoint - Bristol Myers Squibb is focused on strengthening its position in the biopharmaceutical industry through a robust pipeline of late-stage assets and ongoing investments in innovation and shareholder returns [2][3][6]. Group 1: Company Performance and Pipeline - The company has a strong portfolio of early-stage assets that are showing growth potential, with significant opportunities for expansion [2][3]. - Bristol Myers Squibb is anticipating data readouts for six new products this year and has the potential for 11 phase three trials, indicating a rich pipeline for future growth [4][6]. - The company aims to introduce up to 10 new products and over 30 life cycle management opportunities by the end of the decade [4]. Group 2: Financial Outlook - Bristol Myers Squibb is financially strong, allowing for continued investment in business growth and capital returns to shareholders [3][6]. - The company is focused on delivering results from its late-stage assets, which represent the richest pipeline seen in recent years [5][6]. Group 3: Market and Competitive Landscape - The company is aware of competitive threats, particularly from China, which is heavily investing in biopharmaceuticals and aims to replicate the U.S. ecosystem [15][16]. - Bristol Myers Squibb emphasizes the importance of maintaining a strong innovation ecosystem in the U.S. to ensure patient access and affordability [13][16]. Group 4: Role of AI in Drug Development - AI is expected to transform the biopharmaceutical value chain, from basic research to commercialization, with goals to reduce drug development cycle times by 30% [17][18]. - The company utilizes AI models to predict the probability of success for research programs before they enter clinical development [18].